FibroGen (NASDAQ:FGEN) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of FibroGen (NASDAQ:FGEN) in a research note published on Monday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

FibroGen Stock Performance

Shares of FGEN stock opened at $0.37 on Monday. FibroGen has a 1 year low of $0.30 and a 1 year high of $2.93. The firm has a market capitalization of $37.25 million, a PE ratio of -0.15 and a beta of 0.70. The stock has a fifty day moving average of $0.39 and a two-hundred day moving average of $0.83.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.09. The company had revenue of $50.64 million during the quarter, compared to analyst estimates of $33.00 million. During the same period in the previous year, the company earned ($0.65) EPS. Equities research analysts predict that FibroGen will post -0.91 earnings per share for the current fiscal year.

Hedge Funds Weigh In On FibroGen

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Alpine Global Management LLC acquired a new stake in shares of FibroGen in the first quarter valued at $25,000. Delap Wealth Advisory LLC bought a new position in shares of FibroGen during the 1st quarter valued at about $27,000. Accel Wealth Management acquired a new position in shares of FibroGen in the 1st quarter worth approximately $103,000. Point72 DIFC Ltd grew its stake in shares of FibroGen by 734.2% in the 2nd quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 45,990 shares during the last quarter. Finally, Doheny Asset Management CA bought a new stake in shares of FibroGen in the 2nd quarter worth approximately $48,000. 72.71% of the stock is owned by institutional investors.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.